NRx Pharmaceuticals Gets EUA of Zyesami in Nation of Georgia

   By Stephen Nakrosis

NRx Pharmaceuticals, Inc. on Tuesday said Georgia's prime minister and minister of health gave an emergency use authorization for the company's intravenous Zyesami to treat Covid-19.

The company said its Zyesami, or aviptadil, was given the EUA for the treatment of Critical Covid-19.

The company also said a team of physicians, led by Dr. Javier Perez-Fernandez, "a lead investigator in the Phase 2b/3 clinical trial of intravenous Zyesami," will travel to Georgia to train doctors in that country in the use of Zyesami.

NRx said over 1,000 new cases of Covid-19 are being diagnosed in Georgia each day, and there has also been increasing detection of the Delta variant.

At 11:58 p.m. EDT, the company's shares were trading 14.07% higher at $21.32. Volume at the time topped 10.7 million shares, above the stock's 65-day average volume of some 3.2 million.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

July 27, 2021 12:27 ET (16:27 GMT)

NRX Pharmaceuticals (NASDAQ:NRXP)
Historical Stock Chart
From Aug 2024 to Sep 2024